<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Diagn Pathol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Diagn Pathol</journal-id>
      <journal-title-group>
        <journal-title>Diagnostic Pathology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1746-1596</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26746693</article-id>
      <article-id pub-id-type="pmc">4706724</article-id>
      <article-id pub-id-type="publisher-id">453</article-id>
      <article-id pub-id-type="doi">10.1186/s13000-016-0453-y</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Small vessel microembolization and acute glomerulonephritis following infection of aesthetic filler implants</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Cannata-Ortiz</surname>
            <given-names>Pablo</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gracia</surname>
            <given-names>Carolina</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Aouad</surname>
            <given-names>Youssef</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Barat</surname>
            <given-names>Antonio</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Martinez-Gonzalez</surname>
            <given-names>Miguel Angel</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rossello</surname>
            <given-names>Gabriela</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Martin-Cleary</surname>
            <given-names>Catalina</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fern&#xE1;ndez-Fern&#xE1;ndez</surname>
            <given-names>Beatriz</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Requena</surname>
            <given-names>Luis</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Ortiz</surname>
            <given-names>Alberto</given-names>
          </name>
          <address>
            <phone>+34 915504800</phone>
            <email>aortiz@fjd.es</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
          <xref ref-type="aff" rid="Aff5"/>
          <xref ref-type="aff" rid="Aff6"/>
        </contrib>
        <aff id="Aff1"><label/>Pathology, IIS-Fundacion Jimenez Diaz, School of Medicine, UAM, Madrid, Spain </aff>
        <aff id="Aff2"><label/>Nephrology and REDINREN, IIS-Fundacion Jimenez Diaz, School of Medicine, UAM, Madrid, Spain </aff>
        <aff id="Aff3"><label/>Pathology, 12 Octubre Hospital, Madrid, Spain </aff>
        <aff id="Aff4"><label/>Dermatology, IIS-Fundacion Jimenez Diaz, School of Medicine, UAM, Madrid, Spain </aff>
        <aff id="Aff5"><label/>IRSIN, Madrid, Spain </aff>
        <aff id="Aff6"><label/>Laboratory of Nephrology, IIS-Fundacion Jimenez Diaz, Avda Reyes Catolicos 2, 28040 Madrid, Spain </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>8</day>
        <month>1</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>8</day>
        <month>1</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2016</year>
      </pub-date>
      <volume>11</volume>
      <elocation-id>2</elocation-id>
      <history>
        <date date-type="received">
          <day>20</day>
          <month>8</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>1</day>
          <month>1</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Cannata-Ortiz et al. 2016</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>The systemic consequences of esthetic filler injections are poorly understood.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p> We report a patient with a past history of subcutaneous injection of aesthetic filler material in the lower legs, who presented with post-infectious glomerulonephritis following necrotic leg ulcers at the injection site. Kidney biopsy revealed the presence of translucent, non-birefringent microspherical bodies compatible with polymethylmetacrylate (PMMA) microspheres in some capillary lumens. This had not previously been described. PMMA is a biphasic aesthetical filler composed of polymethylmetacrylate microspheres suspended in a biodegradable bovine collagen carrier. The solid phase (PMMA microspheres) persists in tissues for years. Although PMMA was thought to not disseminate systemically, tissue necrosis may have favored systemic dissemination of the microspheres, although entry in the circulation and microembolization at the time of administration cannot be ruled out.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>In conclusion, aesthetic filler implants may cause microembolization into small vessels. Recognition of the characteristic morphology may expedite diagnosis and avoid unnecessary further testing.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Esthetic filler implants</kwd>
        <kwd>Polymethylmetacrylate</kwd>
        <kwd>C3 glomerulopathy</kwd>
        <kwd>Post-infectious glomerulonephritis</kwd>
        <kwd>Nephritic syndrome</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2016</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p>Injected filler agents are used to treat skin wrinkles and for soft tissue augmentation for cosmetic reasons. However, fillers may induce adverse inflammatory reactions that may require biopsy for adequate characterization. Slowly biodegradable or non-resorbable fillers may cause severe reactions that may appear years after the injection, when the patient does not remember which product was injected. Histopathology is the gold standard technique to identify the responsible filler [<xref ref-type="bibr" rid="CR1">1</xref>]. However, fillers are thought to remain locally at the site of injection and unexperienced pathologists may have trouble identifying the images as aesthetic fillers when found in an internal organ. This adds to the complexity of providing an accurate diagnosis as illustrated by this case of glomerulonephritis following infection of subcutaneous filler material.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <p>A 57-year-old woman was admitted for painful lower leg ulcers. Past history included subcutaneous injection of esthetic filler material in the lower legs 20&#xA0;years ago, hypothyroidism and HIV infection on highly active antiretroviral therapy (HAART: raltegravir, abacavir, lamivudine). Viral load was negative and CD4 cells were 600/&#x3BC;l. One year before admission, bilateral torpid lower leg ulcers developed after minor trauma and progressively expanded. She was treated with diclofenac.</p>
      <p>On admission blood pressure was 190/88&#xA0;mmHg (previously normal) and she had extensive necrotic ulceration and edema in both lower legs. Key lab results were serum creatinine 1.5&#xA0;mg/dl (previously 1.0&#xA0;mg/dl), serum albumin 3.5&#xA0;mg/dl, serum cholesterol 139&#xA0;mg/dl, complement factor 3 (C3) nadir 63&#xA0;mg/dl, normal C4, polyclonal hypergammaglobulinemia, urinary albumin:creatinine ratio 2082&#xA0;mg/g, urinary protein:creatinine ratio 3557&#xA0;mg/g and urinary sediment containing 20&#x2013;40 red blood cells/high power field. ANCA, ANA, and anti-GBM were negative. Ulcer cultures grew Group A streptococcus pyogenes.</p>
      <p>Kidney biopsy (two cores; 9 and 11&#xA0;mm long) containing 26 glomeruli, 2 of them completely sclerosed, disclosed diffuse proliferative glomerulonephritis characterized by glomerular hypercellularity due to mesangial proliferation and endocapillary leukocytic infiltration (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). Trichrome staining revealed subepithelial fuchsinophilic deposits. Jones silver stain did not show spikes or basement membrane reduplication (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). Coarse mesangial and peripheral capillary loop staining for C3 was seen on immunofluorescence (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>), without IgG, IgA or IgM deposition. Round translucent, non-birefringent microspherical bodies (30&#x2013;35&#xA0;&#x3BC;m) resembling adipocytes were identified within some capillary lumens (Figs.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref> and <xref rid="Fig2" ref-type="fig">2</xref>). Microspheres were also seen in a globally sclerosed glomerulus (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). In the tubulointerstitial compartment, intratubular red blood cell casts, acute tubular damage and patchy interstitial lymphocytic infiltrates were noted. Vessels showed arteriolar hyalinosis and moderate myointimal hyperplasia. Ultrastructural study revealed subepithelial deposits (&#x2018;humps&#x2019;) (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Diffuse proliferative glomerulonephritis with leukocytic infiltration and polymethyl methacrylate microspheres in glomerular capillary lumens (HE &#xD7;400)</p></caption><graphic xlink:href="13000_2016_453_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Fig. 2</label><caption><p>
<bold>a</bold> PMMA microspheres in a glomerulus (Jones silver stain &#xD7; 400). <bold>b</bold> The finding of PMMA in a sclerosed glomerulus supports the permanent nature of this aesthetic filler (HE &#xD7;400)</p></caption><graphic xlink:href="13000_2016_453_Fig2_HTML" id="MO2"/></fig><fig id="Fig3"><label>Fig. 3</label><caption><p>
<bold>a</bold> Immunofluorescence showing coarse granular C3 deposition along mesangial region with focal peripheral extension adopting a &#x2018;garland&#x2019; pattern. <bold>b</bold> A detail of the glomerular tuft segment between 9 and 11 o&#x2019;clock. Arrowheads pointing subepithelial deposits that correspond to the hump-shaped deposits seen by EM (box <bold>c</bold>). (<bold>a</bold>: IF anti-C3 &#xD7;200; <bold>c</bold>: TEM &#xD7;20000)</p></caption><graphic xlink:href="13000_2016_453_Fig3_HTML" id="MO3"/></fig></p>
      <p>Treatment included local debridement, antibiotics and angiotensin converting enzyme inhibitors. Estimated glomerular filtration rate, C3 and microhematuria normalized at month 3, 5 and 12, respectively, while albuminuria progressively improved over the next 12&#xA0;months (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>). One year after the initial admission, angiotensin converting enzyme inhibitors had been stopped and serum creatinine was 0.9&#xA0;mg/dl, estimated glomerular filtration rate 94&#xA0;ml/min/1.73&#xA0;m2, urinary albumin:creatinine ratio 188&#xA0;mg/g and urinary sediment contained no red blood cells/high power field.<fig id="Fig4"><label>Fig. 4</label><caption><p>Time-course of changes in serum creatinine (mg/dl), urinary albumin/creatinine ratio (UACR in mg/g), hematuria expressed as red blood cells per high power fields (RBC/hpf) and serum complement factor 3 (C3, mg/dl). Green line denotes normal values limit</p></caption><graphic xlink:href="13000_2016_453_Fig4_HTML" id="MO4"/></fig></p>
    </sec>
    <sec id="Sec3">
      <title>Discussion</title>
      <p>The initial differential diagnosis included acute kidney injury due to nonsteroidal anti-inflammatory agents, acute or rapidly progressive glomerulonephritis that may have been superimposed on prior antiretroviral nephrotoxicity or chronic HIV-associated glomerulonephritis [<xref ref-type="bibr" rid="CR2">2</xref>]. Serological studies and renal biopsy narrowed the differential diagnosis to acute postinfectious glomerulonephritis or C3 glomerulopathy, while a potential role of the implanted cosmetic filler material remained unclear.</p>
      <p>Morphology of glomerulonephritis with dominant C3 deposits may underlie both post-infectious glomerulonephritis and C3 glomerulopathy, a recently introduced pathological entity [<xref ref-type="bibr" rid="CR3">3</xref>]. Currently, C3 glomerulopathy is defined as a disease process due to abnormal control of complement activation, deposition, or degradation and characterized by predominant glomerular C3 deposition with electron-dense deposits. However, true post-infectious glomerulonephritis cannot often be differenced from C3 glomerulonephritis based on morphological, clinical and laboratory data available at the time of biopsy. Rather, follow-up of clinical parameters, serum C3 levels and urinary abnormalities over several months may differentiate both entities [<xref ref-type="bibr" rid="CR2">2</xref>]. As in the present case, the decreased serum C3 levels will normalize over 8&#x2013;12&#xA0;weeks in post-infectious glomerulonephritis, although hematuria and albuminuria may persist for years [<xref ref-type="bibr" rid="CR4">4</xref>]. The presence of Group A streptococcus pyogenes infection, the time course of kidney and immunological abnormalities, the renal biopsy and the absence of evidence of abnormal control of complement activation, deposition, or degradation, all support a diagnosis of post-infectious (post-streptococcal) glomerulonephritis. These features also argue against HIV associated glomerulonephritis. The patient was not taking HAART drugs that are clearly nephrotoxic, such as tenofovir, indinavir or atazanavir [<xref ref-type="bibr" rid="CR5">5</xref>&#x2013;<xref ref-type="bibr" rid="CR7">7</xref>]. In this regard, no evidence of proximal tubulopathy (tenofovir) or characteristic urine or kidney tissue crystals (indinavir, atazanavir) were observed and toxic effects of hematuria may account for tubular injury features observed in the biopsy [<xref ref-type="bibr" rid="CR8">8</xref>].</p>
      <p>The presence of microspheres in the kidney biopsy was striking. While the patient did not recall the nature of the injected material, the histologic appearance was consistent with polymethylmetacrylate (PMMA), a biphasic aesthetical filler composed of biodegradable bovine collagen and PMMA microspheres which persist in tissues for years [<xref ref-type="bibr" rid="CR1">1</xref>]. There is longstanding clinical experience with this material and only local (subcutaneous) inflammatory granulomatous reactions are documented [<xref ref-type="bibr" rid="CR9">9</xref>]. We are not aware of prior reports of systemic dissemination of PMMA microspheres in humans. PMMA was thought to not disseminate systemically, but it may generate local inflammatory reactions spontaneously or following a trigger [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. The injection of the filler several years ago may explain the absence of a local kidney inflammatory granulomatous reaction to PMMA microspheres, and their presence in a sclerosed glomerulus supports their permanent nature. The presence of PMMA in the lower legs may have favored the torpid course of the ulcers. Conversely, tissue necrosis may have favored systemic dissemination of the microspheres, although we can only speculate as to their contribution to the clinical presentation. PMMA does not appear to have triggered the present inflammatory response since emboli were present in the absence of local inflammation. However, it may have contributed to local ischemia and tubular injury. Entry in the circulation and microembolization at the time of filler administration, many years ago, cannot be ruled out.</p>
    </sec>
    <sec id="Sec4">
      <title>Conclusions</title>
      <p>The final diagnosis was acute post-streptococcal glomerulonephritis with esthetic filler implants microembolization into small vessels. Esthetic filler implant microembolization is here described for the first time. We conclude that esthetic filler implants may cause microembolization into small vessels. Recognition of the characteristic morphology may expedite diagnosis and avoid unnecessary further testing.</p>
    </sec>
    <sec id="Sec5">
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient for publication of this Case Report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors declare that they have no competing interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contributions</bold>
        </p>
        <p>PCO, AB and MAMG performed and analyzed the histological studies, LR analyzed the histology and provided critical insights, CG, YA, GR, CMC and BFF participated in the getting the clinical data and patient consent, AO drafted the manuscript and coordinated the effort. All authors critically read, made suggestions for improvement and approved the final manuscript.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>AO and CMC were supported by ISCIII and FEDER funds PI13/00047, REDinREN RD012/0021, Comunidad de Madrid CIFRA S2010/BMD-2378 and Programa Intensificaci&#xF3;n Actividad Investigadora. BFF by ISCIII Joan Rodes.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Requena</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Requena</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Christensen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Zimmermann</surname>
              <given-names>US</given-names>
            </name>
            <name>
              <surname>Kutzner</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Cerroni</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Adverse reactions to injectable soft tissue fillers</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2011</year>
          <volume>64</volume>
          <issue>1</issue>
          <fpage>1</fpage>
          <lpage>34</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jaad.2010.02.064</pub-id>
          <pub-id pub-id-type="pmid">21167403</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rosenberg</surname>
              <given-names>AZ</given-names>
            </name>
            <name>
              <surname>Naicker</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Winkler</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Kopp</surname>
              <given-names>JB</given-names>
            </name>
          </person-group>
          <article-title>HIV-associated nephropathies: epidemiology, pathology, mechanisms and treatment</article-title>
          <source>Nat Rev Nephrol</source>
          <year>2015</year>
          <volume>11</volume>
          <issue>3</issue>
          <fpage>150</fpage>
          <lpage>60</lpage>
          <pub-id pub-id-type="doi">10.1038/nrneph.2015.9</pub-id>
          <pub-id pub-id-type="pmid">25686569</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pickering</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>D&#x2019;Agati</surname>
              <given-names>VD</given-names>
            </name>
            <name>
              <surname>Nester</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Haas</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Appel</surname>
              <given-names>GB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>C3 glomerulopathy: consensus report</article-title>
          <source>Kidney Int</source>
          <year>2013</year>
          <volume>84</volume>
          <issue>6</issue>
          <fpage>1079</fpage>
          <lpage>89</lpage>
          <pub-id pub-id-type="doi">10.1038/ki.2013.377</pub-id>
          <pub-id pub-id-type="pmid">24172683</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hoy</surname>
              <given-names>WE</given-names>
            </name>
            <name>
              <surname>White</surname>
              <given-names>AV</given-names>
            </name>
            <name>
              <surname>Dowling</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sharma</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Bloomfield</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tipiloura</surname>
              <given-names>BT</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Post-streptococcal glomerulonephritis is a strong risk factor for chronic kidney disease in later life</article-title>
          <source>Kidney Int</source>
          <year>2012</year>
          <volume>81</volume>
          <issue>10</issue>
          <fpage>1026</fpage>
          <lpage>32</lpage>
          <pub-id pub-id-type="doi">10.1038/ki.2011.478</pub-id>
          <pub-id pub-id-type="pmid">22297679</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hara</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Suganuma</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Yanagisawa</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Imamura</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hishima</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ando</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Atazanavir nephrotoxicity</article-title>
          <source>Clin Kidney J</source>
          <year>2015</year>
          <volume>8</volume>
          <issue>2</issue>
          <fpage>137</fpage>
          <lpage>42</lpage>
          <pub-id pub-id-type="doi">10.1093/ckj/sfv015</pub-id>
          <pub-id pub-id-type="pmid">25815168</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Izzedine</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Lescure</surname>
              <given-names>FX</given-names>
            </name>
            <name>
              <surname>Bonnet</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>HIV medication-based urolithiasis</article-title>
          <source>Clin Kidney J</source>
          <year>2014</year>
          <volume>7</volume>
          <issue>2</issue>
          <fpage>121</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1093/ckj/sfu008</pub-id>
          <pub-id pub-id-type="pmid">25852859</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fernandez-Fernandez</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Montoya-Ferrer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sanz</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Sanchez-Ni&#xF1;o</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Izquierdo</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Poveda</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Tenofovir nephrotoxicity: 2011 update</article-title>
          <source>AIDS Res Treat</source>
          <year>2011</year>
          <volume>2011</volume>
          <fpage>354908</fpage>
          <pub-id pub-id-type="pmid">21716719</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moreno</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Mart&#xED;n-Cleary</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Guti&#xE9;rrez</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Toldos</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Blanco-Colio</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Praga</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>AKI associated with macroscopic glomerular hematuria: clinical and pathophysiologic consequences</article-title>
          <source>Clin J Am Soc Nephrol</source>
          <year>2012</year>
          <volume>7</volume>
          <issue>1</issue>
          <fpage>175</fpage>
          <lpage>84</lpage>
          <pub-id pub-id-type="doi">10.2215/CJN.01970211</pub-id>
          <pub-id pub-id-type="pmid">22096039</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Park</surname>
              <given-names>TH</given-names>
            </name>
            <name>
              <surname>Seo</surname>
              <given-names>SW</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>CH</given-names>
            </name>
          </person-group>
          <article-title>Clinical experience with polymethylmethacrylate microsphere filler complications</article-title>
          <source>Aesthetic Plast Surg</source>
          <year>2012</year>
          <volume>36</volume>
          <issue>2</issue>
          <fpage>421</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1007/s00266-011-9803-z</pub-id>
          <pub-id pub-id-type="pmid">21909864</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rosa</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>de Magalh&#xE3;es</surname>
              <given-names>AV</given-names>
            </name>
            <name>
              <surname>de Macedo</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <article-title>An experimental study of tissue reaction to polymethyl methacrylate (PMMA) microspheres (Artecoll) and dimethylsiloxane (DMS) in the mouse</article-title>
          <source>Am J Dermatopathol</source>
          <year>2008</year>
          <volume>30</volume>
          <issue>3</issue>
          <fpage>222</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1097/DAD.0b013e31816906d2</pub-id>
          <pub-id pub-id-type="pmid">18496421</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fischer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Metzler</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Schaller</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Cosmetic permanent fillers for soft tissue augmentation: a new contraindication for interferon therapies</article-title>
          <source>Arch Dermatol</source>
          <year>2007</year>
          <volume>143</volume>
          <issue>4</issue>
          <fpage>507</fpage>
          <lpage>10</lpage>
          <pub-id pub-id-type="doi">10.1001/archderm.143.4.507</pub-id>
          <pub-id pub-id-type="pmid">17438184</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
